$MMS

The FDA has approved leucovorin as the first drug specifically aimed at treating a rare genetic disorder, which could lead to increased usage in a niche market. The approval follows its promotion by the Trump administration as a possible treatment for autism, raising questions about its broader implications in the pharmaceutical sector. This move may positively impact companies involved in the production and distribution of leucovorin or related therapies. However, the initial hype around its use for autism might lead to mixed public reactions. Investors should monitor the stock performance of associated pharmaceutical companies closely.